Archive - September 2019
FDA Approves Ofev (nintedanib) for Interstitial Lung Disease Associated with Systemic Sclerosis or Scleroderma (SSc-ILD)
Study Links Sugar-Free Soft Drinks To Higher Risk Of Death
70% Of All Cardiovascular Disease Deaths Caused By 14 Risk Factors
Novartis’ lung cancer drug wins FDA Breakthrough Therapy Designation
Only 1 week left to enter into the 2019 Sales Awards!
EU Marketing Authorisation granted for Lonsurf
LIVI partners with Boots
EU approval for Tecentriq-based NSCLC combo